<table>
<thead>
<tr>
<th>類型</th>
<th>金沢大学医学情報リポジトリの利用に関する条件</th>
</tr>
</thead>
<tbody>
<tr>
<td>内容</td>
<td>金沢大学医学情報リポジトリに登録されているコンテンツの著作権は、執筆者、出版社（学協会）などが有します。</td>
</tr>
<tr>
<td>利用</td>
<td>金沢大学医学情報リポジトリに登録されているコンテンツの利用については、著作権法に規定されている私的使用や引用などの範囲内で行ってください。</td>
</tr>
<tr>
<td>要求</td>
<td>著作権法に規定されている私的使用や引用などの範囲を超える利用を行う場合には、著作権者の許諾を得てください。ただし、著作権者から著作権等管理事業者（学術著作権協会、日本著作出版権管理システムなど）に権利委託されているコンテンツの利用手続については、各著作権等管理事業者に確認してください。</td>
</tr>
</tbody>
</table>

The efficacy of radiation monotherapy for Tolosa-Hunt syndrome

Author(s)
Furukawa, Yutaka; Yamaguchi, Wataru; Ito, Kiyoaki; Hamada, Toshio; Miyaji, Hirobumi; Tamamura, Hiroyasu; Yamada, Masahito

Citation
Journal of Neurology, 257(2): 288-290

Issue Date
2009

Type
Journal Article

Text version
author

URL
http://hdl.handle.net/2297/19891

Right
http://dspace.lib.kanazawa-u.ac.jp/dspace/
The efficacy of radiation monotherapy for Tolosa-Hunt syndrome.

Yutaka Furukawa\textsuperscript{1,3}, Wataru Yamaguchi\textsuperscript{1}, Kiyoaki Ito\textsuperscript{1}, Toshio Hamada\textsuperscript{1}, Hirobumi Miyaji\textsuperscript{1}, Hiroyasu Tamamura\textsuperscript{2}, and Masahito Yamada\textsuperscript{3}

\textsuperscript{1}Department of Neurology and the \textsuperscript{2}Department of Nuclear Medicine, Fukui Prefectural Hospital, Fukui, and the \textsuperscript{3}Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.

Key words: corticosteroids, radiation therapy, Tolosa-Hunt syndrome

Column title: Radiation therapy for Tolosa-Hunt syndrome

**Corresponding author:** Yutaka Furukawa, MD

Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8640, Japan

Telephone: +81-76-265-2292   Fax: +81-76-234-4253

E-mail: furukawa@med.kanazawa-u.ac.jp
Sirs,

Tolosa-Hunt syndrome (THS) is characterized by painful ophthalmoplegia due to an idiopathic chronic granulomatous inflammation of the cavernous sinus.[9] THS usually improves with corticosteroids, however, in cases showing an insufficient effect of corticosteroid therapy or side effects, alternative therapies such as immunosuppressive agents[3] or focal radiation therapy have been reported.[2,5-7] We describe a patient with THS who was successfully treated with radiation monotherapy.

A 36-year-old man with chronic hepatitis B and impaired glucose tolerance since age 30 developed acute left orbital pain and double vision at the end of July 2006. Neurologic examination on 3 August 2006 demonstrated only mild restriction of abduction of the left eye. Magnetic resonance imaging (MRI) of the brain showed no abnormality including the cavernous sinus region at that time. His illness progressed rapidly and he was admitted to our hospital on 14 August 2006.

On admission, body temperature and blood pressure were normal. Neurologic examination demonstrated almost complete ophthalmoplegia in all directions and
blepharoptosis without pupil abnormality on the left. Spontaneous left ophthalmic pain was also reported. There were no ophthalmic symptoms on the right and there were no symptoms of lower cranial nerves on both sides. Urinalysis and routine hematological examination were normal. Blood chemistry examination demonstrated mild elevation of aspartate aminotransferase (60 IU/L; normal range 11-34 IU/L), alanine aminotransferase (151 IU/L; normal range 6-39 IU/L) and glycohemoglobin A1c (6.1%; normal range 4.3-5.8 %). Surface antigen and core antibody of hepatitis B virus were positive. The following immunological and inflammatory investigations were normal or negative; antinuclear antibody, cytoplasmic and perinuclear antineutrophil cytoplasmic antibody, angiotensin converting enzyme level and β-D glucan. Chest radiography and Gallium scintigraphy of the whole body showed no abnormality suggestive of systemic inflammatory disease. Cerebrospinal fluid examinations were normal including cytology and culture for bacteria and mycobacteria. Brain MRI showed abnormal soft tissue enhanced with gadolinium within the left cavernous sinus (Figure).

Based on a diagnosis of THS, we first considered corticosteroid therapy for THS
with simultaneous antiviral therapy for hepatitis; however, the patient refused corticosteroid therapy because of the possible exacerbation of hepatitis. One week after admission, the left pupil was dilated and light response was diminished, indicating progression of THS. Thereafter, the patient received a total of 30 Gy in 15 fractions focused on the left cavernous sinus by three-dimensional conformal radiotherapy (3D-CRT).

Left blepharoptosis and ophthalmoplegia gradually improved within two weeks after the initiation of radiation therapy; blepharoptosis had almost completely disappeared by the middle of October 2006. Ophthalmoplegia also completely recovered by the beginning of January 2007. The illness remained in remission without any side effects during the observation period of one year.

However, the response to corticosteroid therapy could not be evaluated due to chronic hepatitis B, our patient fulfilled the remaining diagnostic criteria of THS by the International Headache Society,[4] and was successfully treated with radiation monotherapy.

Previous reports for radiation therapy in THS are shown in the Table.[2, 5-7] All
four reported patients had received corticosteroid as an initial treatment, and radiation therapy was added because corticosteroid therapy showed insufficient effects (steroid dependence or steroid resistance) or severe side effects. It should be noted that our patient received only radiation therapy resulting in improvement of THS. To our knowledge, there has not been any previous report of radiation monotherapy for THS.

There has not been any consensus regarding the dose of radiation for THS. However, low dose radiation seems to be sufficiently effective as shown in the Table. The response of our patient demonstrated that low dose radiation monotherapy is effective in THS.

Additionally our patient and previously described patients who had received low dose radiation therapy for THS had no adverse effects related to the therapy during observation period (maximum 8 years). In case of exposure of the cavernous sinus to radiation, adverse effect on visual pathway and cranial nerves within the cavernous sinus should be concerned,[8] however, low dose irradiation to cavernous sinus by 3D-CRT method may be safe, referring to the neuronal tissue tolerance to irradiation (e.g. tolerance dose at the 5% complication rate within 5 years from treatment (TD 5/5))
for optic nerve and chiasma is 50 Gy).[1] Radiation monotherapy would be a useful and safe therapeutic option when it is difficult or contraindicated to use corticosteroids due to complications.
Acknowledgement

The authors thank Dr. N. Ibe (Department of Gastroenterology, Fukui Prefectural Hospital) for advice on hepatology.
References


Figure legend

Axial sections of T1-weighted images before (A) and after enhancement with gadolinium (B). The soft tissue within the left cavernous sinus with intermediate signal intensity shows obvious gadolinium enhancement (arrow heads).
<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Authors [reference]</th>
<th>Age (y.o)</th>
<th>Gender</th>
<th>Corticosteroid therapy</th>
<th>Immunosuppressant therapy</th>
<th>Dose of radiation (Gy)</th>
<th>Treatment period of radiation</th>
<th>Efficacy of radiation</th>
<th>Interval between initiation of radiation and improvement of the symptoms</th>
<th>Recurrence after radiation</th>
<th>Adverse effect related to radiation therapy</th>
<th>Observation period</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Nasr YG et al. (1987) [7]</td>
<td>49</td>
<td>female</td>
<td>yes</td>
<td>no</td>
<td>50</td>
<td>not available</td>
<td>yes</td>
<td>not available</td>
<td>no</td>
<td>not available</td>
<td>2 years</td>
</tr>
<tr>
<td>2.</td>
<td>Larner JM et al. (1991) [5]</td>
<td>50</td>
<td>male</td>
<td>yes</td>
<td>no</td>
<td>20</td>
<td>5.5 months</td>
<td>yes</td>
<td>not available</td>
<td>no</td>
<td>not available</td>
<td>11 months</td>
</tr>
<tr>
<td>3.</td>
<td>Mormont E et al. (2000) [6]</td>
<td>32</td>
<td>female</td>
<td>yes</td>
<td>yes (azathioprine)</td>
<td>30</td>
<td>22 days</td>
<td>yes</td>
<td>15 days</td>
<td>no</td>
<td>no</td>
<td>3 years</td>
</tr>
<tr>
<td>4.</td>
<td>Foubert-Samier A et al. (2005) [2]</td>
<td>41</td>
<td>male</td>
<td>yes</td>
<td>no</td>
<td>20</td>
<td>not available</td>
<td>yes</td>
<td>not available</td>
<td>no</td>
<td>no</td>
<td>8 years</td>
</tr>
<tr>
<td>5.</td>
<td>Present patient</td>
<td>36</td>
<td>male</td>
<td>no</td>
<td>no</td>
<td>30</td>
<td>21 days</td>
<td>yes</td>
<td>2 weeks</td>
<td>no</td>
<td>no</td>
<td>1 year</td>
</tr>
</tbody>
</table>
Figures